Autolus lands $250M debt facility from Perceptive as AUCATZYL sales double
What's the deal? Autolus Therapeutics (Nasdaq: AUTL) has secured a five-year senior credit facility of up to $250 million from Perceptive Advisors. An initial $75 million tranche closed on July 30, 2026, with a further $25 million available for six months and up to $150 million more tied to revenue milestones.
Who's backing it? Perceptive Advisors, a well-known healthcare-focused investment firm, leads the interest-only facility. The debt carries one-month SOFR — with a 3.50% floor — plus 7.25%, and Autolus issued Perceptive a warrant for up to 3.5 million ADSs at $1.9314 each.
The revenue story: The financing lands alongside preliminary second-quarter results. Autolus reported about $45 million in net product revenue from AUCATZYL, its cancer therapy, up roughly 70% from Q1 2026 and more than 100% from Q2 2025.
The company raised full-year 2026 sales guidance to $140–$150 million, from $120–$135 million. Gross margin swung from roughly -20% in the second half of 2025 to about 35% in the first half of 2026, helped by higher use at existing treatment centres and new ones coming online.
What's the endgame? The first two tranches, totalling $100 million, plus existing cash are expected to fund operations into Q2 2028. That gives Autolus runway to keep scaling AUCATZYL's commercial rollout.
What could go wrong? The debt is not cheap, and the warrant carries potential dilution for shareholders. Continued growth also depends on the roughly $150 million in milestone-linked capacity, which is not guaranteed.
The signal: Backing from a specialist investor like Perceptive gives commercial-stage biotechs a non-dilutive path to fund growth without leaning on volatile equity markets — a route that becomes more attractive as revenue starts to build. AUTL shares rose 7.38% to $1.60 following the news.
Read more: StockTitan
Image credit: Generated with Gemini
